In short
This article explores the use of panitumumab, a monoclonal antibody drug, in various clinical trials for cancer treatment. Panitumumab targets the epidermal growth factor receptor (EGFR) and is being studied in colorectal cancer, head and neck cancer, and other types of tumors. The trials aim to evaluate panitumumab's efficacy, safety, and potential benefits when used alone or in combination with other treatments like chemotherapy and radiation therapy.
At a glance
- Drug Name
- Panitumumab (also known as Vectibix)
- Drug Type
- Monoclonal antibody targeting EGFR
- Main Cancer Types Studied
- Colorectal cancer, head and neck squamous cell carcinoma, small bowel cancer
- Common Dosing
- 6-9 mg/kg intravenously every 2 weeks
- Key Outcome Measures
- Response rate, progression-free survival, overall survival, safety profile
- Combination Therapies
- Studied with chemotherapy (e.g., FOLFIRI) and radiation therapy
- Patient Selection
- Often focuses on patients with wild-type KRAS/NRAS genes
- Common Side Effects
- Skin disorders, electrolyte abnormalities, infusion reactions
What is Panitumumab?
Panitumumab, also known by its brand name Vectibix, is a type of medication called a monoclonal antibody. Monoclonal antibodies are laboratory-made proteins that act like human antibodies in the immune system. They are designed to recognize and attach to specific proteins in the body.
How Does Panitumumab Work?
Panitumumab works by targeting a specific protein called epidermal growth factor receptor (EGFR) that is found on the surface of some cancer cells. EGFR helps cancer cells grow and divide. By attaching to EGFR, panitumumab blocks its function and helps prevent cancer cells from growing.
What Conditions Does Panitumumab Treat?
Panitumumab is primarily used to treat:
- Metastatic Colorectal Cancer: This is cancer that has spread from the colon or rectum to other parts of the body. Panitumumab is used in patients whose cancer has a normal (wild-type) RAS gene.
- Head and Neck Squamous Cell Carcinoma: This is a type of cancer that begins in the flat cells that line the inside of the mouth, nose, and throat.
How is Panitumumab Administered?
Panitumumab is typically given as an intravenous (IV) infusion, which means it's delivered directly into your bloodstream through a vein. The usual dose is 6 mg/kg of body weight, given every two weeks. The infusion usually takes about 60 to 90 minutes. Your doctor will determine the appropriate dose and schedule based on your specific condition and response to treatment.
Current Clinical Trials
Several clinical trials are currently studying panitumumab to improve its effectiveness and explore new uses:
- Combining panitumumab with different chemotherapy regimens like FOLFOXIRI (a combination of multiple chemotherapy drugs) for metastatic colorectal cancer.
- Using panitumumab in combination with targeted liver therapy (hepatic arterial infusion) for colorectal cancer that has spread to the liver.
- Exploring intermittent dosing schedules to potentially reduce side effects while maintaining effectiveness.
- Using a special form of panitumumab (Zr-89 labeled) as an imaging tool to detect cancer spread in head and neck cancer patients.
Potential Side Effects
Like all medications, panitumumab can cause side effects. Common side effects may include:
- Skin reactions (rash, itching, dryness)
- Diarrhea
- Nausea
- Fatigue
- Fever
Your healthcare team will monitor you closely for any side effects and can help manage them if they occur. It's important to report any new symptoms or changes in your health to your doctor.